Literature DB >> 16793577

Ketogenic diet in patients with myoclonic-astatic epilepsy.

Roberto Horacio Caraballo1, Ricardo Oscar Cersósimo, Diego Sakr, Araceli Cresta, Nidia Escobal, Natalio Fejerman.   

Abstract

For more than 80 years, the ketogenic diet has been used as an alternative to antiepileptic drugs for patients with refractory epilepsy. Myoclonic-astatic epilepsy in early childhood is one of the malignant epilepsy syndromes that often proves refractory to antiepileptic drugs treatment. Objective. In this prospective study we assess the efficacy and tolerability of the ketogenic diet in patients with myoclonic-astatic epilepsy. Material and methods. Between March 1, 1990 and August 31, 2004, 30 patients who met diagnostic criteria of myoclonic-astatic epilepsy were seen at our department. Eleven of them were placed on the ketogenic diet using the Hopkins protocol and were followed for a minimum of 18 months. Results. The children had previously received a mean of 5.2 different antiepileptic drugs and were on a mean of 2.2 antiepileptic drugs when the diet was started. Eighteen months after initiating the diet, six of the patients (54.5%) remained on the diet. Two patients (18%) were seizure-free, two (18%) had a 75-99% decrease in seizures, and the remaining two children (18%) had a 50% to 74% decrease in seizures. The first two patients were tapered off the diet after remaining seizure-free, without antiepileptic drugs for several years. In the two patients who had sporadic seizures, antiepileptic drugs were reduced to one, and in the last two the seizure frequency was significantly reduced. No differences in seizure control were found when compared for age, sex, or seizure type. Five of our patients discontinued the ketogenic diet in less than 3 months (four because of lack of effectiveness and one because of persistent vomiting). Conclusion. The ketogenic diet is a promising therapy for patients with myoclonic-astatic epilepsy, with over half the children showing a > 50% reduction in seizures, and seizure-freedom in 18%. In drug resistant cases of myoclonic-astatic epilepsy, the diet should be considered early in the course of this syndrome and not as a last resort.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793577

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  20 in total

1.  Purines and the Anti-Epileptic Actions of Ketogenic Diets.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin; Jeremy Gawryluk; Xuesong Chen; Jonathan D Geiger
Journal:  Open Neurosci J       Date:  2010-01-01

Review 2.  Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies.

Authors:  Qian-Yun Cai; Zhong-Jie Zhou; Rong Luo; Jing Gan; Shi-Ping Li; De-Zhi Mu; Chao-Min Wan
Journal:  World J Pediatr       Date:  2017-07-12       Impact factor: 2.764

3.  SLC6A1 Mutation and Ketogenic Diet in Epilepsy With Myoclonic-Atonic Seizures.

Authors:  Samantha Palmer; Meghan C Towne; Phillip L Pearl; Renee C Pelletier; Casie A Genetti; Jiahai Shi; Alan H Beggs; Pankaj B Agrawal; Catherine A Brownstein
Journal:  Pediatr Neurol       Date:  2016-07-28       Impact factor: 3.372

Review 4.  The changing face of dietary therapy for epilepsy.

Authors:  Ludovica Pasca; Valentina De Giorgis; Joyce Ann Macasaet; Claudia Trentani; Anna Tagliabue; Pierangelo Veggiotti
Journal:  Eur J Pediatr       Date:  2016-09-01       Impact factor: 3.183

Review 5.  Dietary therapies for epilepsy: future research.

Authors:  Sudha K Kessler; Elizabeth G Neal; Carol S Camfield; Eric H Kossoff
Journal:  Epilepsy Behav       Date:  2011-03-26       Impact factor: 2.937

6.  Early EEG improvement after ketogenic diet initiation.

Authors:  Sudha Kilaru Kessler; Paul R Gallagher; Renée A Shellhaas; Robert R Clancy; A G Christina Bergqvist
Journal:  Epilepsy Res       Date:  2011-02-23       Impact factor: 3.045

Review 7.  Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies.

Authors:  Detlev Boison; Jong M Rho
Journal:  Neuropharmacology       Date:  2019-08-13       Impact factor: 5.250

8.  The ketogenic diet: uses in epilepsy and other neurologic illnesses.

Authors:  Kristin W Barañano; Adam L Hartman
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

Review 9.  The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies.

Authors:  Marwan Maalouf; Jong M Rho; Mark P Mattson
Journal:  Brain Res Rev       Date:  2008-09-25

Review 10.  Ketogenic diet, neuroprotection, and antiepileptogenesis.

Authors:  Madhuvika Murugan; Detlev Boison
Journal:  Epilepsy Res       Date:  2020-08-19       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.